Interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced ovarian cancer

International Journal of Oncology

Volumn 27, Issue 4, 2005, Pages 1039-1046

  Recchia, Francesco ^a,b   Saggio, Gaetano ^a   Cesta, Alisia ^a   Candeloro, Giampiero ^a   Nuzzo, Antonio ^c   Lombardo, Marco ^d   Carta, Gaspare ^e   Rea, Silvio ^b,e  

^a Ospedale Civile di Avezzano   (Italy)

^b Fondazione 'Carlo Ferri'   (Italy)

^c Ospedale Civile di Lanciano   (Italy)

^d Ospedale Civile di Pescara   (Italy)

^e UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

13 cis retinoic acid; Advanced ovarian cancer; Interleukin 2; Maintenance therapy

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 2; ISOTRETINOIN; RETINOIC ACID; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; COHORT ANALYSIS; CYTOLOGY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOTHERAPY; LYMPHOCYTE; METABOLISM; METHODOLOGY; MIDDLE AGED; NATURAL KILLER CELL; OVARY TUMOR; PHASE 2 CLINICAL TRIAL; TIME; TREATMENT OUTCOME; TUMOR CELL LINE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; ISOTRETINOIN; KILLER CELLS, NATURAL; LYMPHOCYTES; MIDDLE AGED; OVARIAN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; TRETINOIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33644820746     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.27.4.1039     Document Type: Article

References (40)

1. The International Collaborative Ovarian Neoplasm Group: Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 360: 505-515, 2002.
2. Ozols RF: Update on the management of ovarian cancer. Cancer J 8 (Suppl. 1): S22-S30, 2002.
3. Lotz JP, Cure H, Janvier M, Asselain B, Morvan 'F, Legros M, Audhuy B, Biron P, Guillemot M, Goubet J, Laadem A, Cailliot C, Maignan CL, Delozier T, Glaisner S, Maraninchi D, Roche H and Gisselbrecht C: High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol. Eur J Cancer 41: 71-80. 2005.
4. Debby A, Levy T, Hayat H, Brenner Y, Glezerman M and Menczer J: Whole-abdomen, single-dose consolidation radiotherapy in patients with pathologically confirmed complete remission of advanced ovarian epithelial carcinoma: a long-term survival analysis. Int J Gynecol Cancer 14: 794-798, 2004.
5. Varia MA, Stehman FB, Bundy BN, Benda JA, Clarke-Pearson DL, Alvarez RD and Long HJ: Gynecologic Oncology Group. Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group. J Clin Oncol 21: 2849-2855, 2003.
6. Berek JS, Taylor PT, Gordon A, Cunningham MJ, Finkler N, OIT J Jr, Rivkin S, Schultes BC, Whiteside TL and Nicodemus CF: Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol 22: 3507-3516, 2004.
7. Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, Jiang C and Alberts D: Southwest Oncology Group; Gynecologic Oncology Group: phase III randomised study of 12 versus three months of single-agent paclitaxel in patients with advanced ovarian cancer with complete response to a platinum and paclitaxel-based chemotherapy: A southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21: 2460-2465, 2003.
8. Alberts DS, Liu PY, Hannigan EV, OToole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK and Du Beshter B: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335: 1950-1955, 1996.
9. Freedman RS and Platsoucas CD: Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes. Cancer Treat Res 82: 115-146, 1996.
10. Folkman J: The role of angiogenesis in tumor growth. Semin Cancer Biol 2: 65-71, 1992.
11. Mackall CL, Fleisher TA, Brown MR, Magrath IT, Shad AT, Horowitz ME, Wexler LH, Adde MA, McClure LL and Gress RE: Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 84: 2221-2228, 1994.
12. Wise JA, Mokyr MB and Dray S: Effect of low-dose cyclophosphamide therapy on specific and non-specific T celldependent immune responses of spleen cells from mice bearing large MOPC-315 plasmacytomas. Cancer Immunol Immunother 27: 191-197, 1988.
13. Riesco A: Five-year cancer cure: relation to total amount of peripheral lymphocytes and neutrophils. Cancer 25: 135-140, 1970.
14. Fumagalli LA, Vinke J, Hoff W, Ypma E, Brivio F and Nespoli A: Lymphocytes independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy. J Immunother 26: 394-402, 2003.
15. Dadmarz RD, Ordoubadi A, Mixon A, Thompson CO, Barracchini KC, Hijazi YM, Steller MA, Rosenberg SA and Schwartzentruber DJ: Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class Il-restricted fashion. Cancer J Sci Am 5: 263, 1996.
16. Santin AD, Bellone S, Ravaggi A, Pecorelli S, Cannon MJ and Parham GP: Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells. Obstet Gynecol 96: 422-430, 2000.
17. Alvarez Secord A, Sayer R, Snyder SA, Broadwater G, Rodriguez GC, Berchuck A and Blackwell K: The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer. Gynecol Oncol 94: 74-79, 2004.
18. Recchia F, De Filippis S, Rosselli M, Saggio G, Cesta A, Fumagalli L and Rea S: Phase IB study of subcutaneously administered Interleukin-2 in combination with 13-cis retinoic acid as maintenance therapy in advanced cancer. Clin Cancer Res 7: 1251-1257,2001.
19. Recchia F, De Filippis S, Rosselli M, Saggio G, Fumagalli L and Rea S: Interleukin-2 and 13-cis retinoic acid in the treatment of Minimal residual disease. A phase II study. Int J Oncol 20: 1275-1282,2002.
20. Recchia F, De Filippis S, Saggio G, Amiconi G, Cesta A, Carta G and Rea S: Phase I study of liposomal doxorubicin and oxaliplatin as salvage chemotherapy in advanced ovarian cancer. Anticancer Drugs 14: 633-688, 2003.
21. Recchia F, De Filippis S, Rosselli M, Saggio G, Carta G and Rea S: Primary chemotherapy in stage IV ovarian cancer. A prospective phase II study. Eur J Gynaecol Oncol 4: 287-291, 2001.
22. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L and Lewis JL Jr: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9: 389-393, 1991.
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
24. Kaplan EL and Meier P: Non-parametric estimation from incomplete observations. J Am Statist Assoc 53: 457-481, 1958.
25. Recchia F, De Filippis S, Pompili PL, Rosselli M, Saggio G, Ciorra A, Piccinini M and Rea S: Carboplatin, vindesine, 5- fluorouracil- leucovorin and 13-cis retinoic acid in the treatment of advanced non-small cell lung cancer. A phase II study. Clin Ter 150: 269-274, 1999.
26. Recchia F, Sica G, De Filippis S, Rosselli M, Saggio G, Guerriero G, Pompili PL and Rea S: Cisplatin, vindesine, mitomycin-c and 13-cis retinoic acid in the treatment of advanced non-small cell lung cancer. A phase II pilot study. Anticancer Res 20: 1985-1990, 2000.
27. Chalmers TC, Celano P, Sacks HS and Smith H Jr: Bias treatment assignment in controlled clinical trials. N Engl J Med 309: 1358-1361, 1983.
28. Sacks H, Chalmers TC and Smith H Jr: Randomized versus historical controls for clinical trials. Am J Med 72: 233-240, 1982.
29. Coldiz GA, Miller JN and Mosteller F: How study design effects outcome in comparisons of therapy I. Surg Sat Med 8: 441-454, 1989.
30. Miller JN, Coldiz GA and Mosteller F: How study design effects outcome in comparisons of therapy II. Surg Sat Med 8: 455-466, 1989.
31. Concato J, Shah N and Horwitz RI: Randomized controlled trials, observational studies and the hierarchy of research designs. N Engl J Med 342: 1887-1892, 2000.
32. Benson BA and Hartz A: A comparison of observation studies and randomized, controlled trials. N Engl J Med 342: 1878-1886, 2000.
33. Parmar MK, Ledermann JA, Colombo N, Du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Trope C, ACON and AGO Collaborators: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361: 2099-2106, 2003.
34. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC and Coukos G: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348: 252-254, 2003.
35. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR and Louie AC: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13: 688-696, 1995.
36. Nishida N, Yano H, Komai K, Nishida T, Kamura T and 'Kojiro M: Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer 101: 1364-1374,2004.
37. Oikawa T, Hirotani K, Nakamura O, Shudo K, Hiragun A and Iwaguchi T: A highly potent antiangiogenic activity of retinoids. Cancer Lett 48: 157-162, 1989.
38. Lindemann A, Brossart P, Hoffken K, Flasshove M, Voliotis D, Diehl V, Hecker G, Wagner H and Mertelsmann R: Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: a phase-IB study. Cancer Immunol Immunother 37: 307-315, 1993.
39. Gohring B, Riemann, D, Rebmann U, Heynemann H, Schabel J and Langner J: Prognostic value of immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-α in combination with 5FU. Urol Res 24: 297-303, 1996.
40. Hemberg M: Lymphocyte subsets as prognostic markers for cancer patients receiving immunomodulative therapy. Med Oncol 16: 145-153, 1999.